Sanofi to acquire Protein Sciences

Sanofi announced today it will acquire Protein Sciences, a privately held vaccines biotechnology company based in Meriden, Connecticut in the United States. Under the terms of the agreement, Sanofi will make an upfront payment of $650 million and pay up to $100 million upon achievement of certain milestones.

Protein Sciences received approval from the US Food and Drug Administration (FDA) in October 2016 for their Flublok Quadrivalent Influenza Vaccine (QIV). Flublok is the only recombinant protein-based influenza vaccine approved by the FDA.

Read more

Opportunity Knocks for Canadian Businesses in the Global Market for Climate-Friendly Goods and Services

Canada has a competitive edge in a few key climate-friendly technologies including wind and solar power, energy efficient turbines, and waste management, according to a new Conference Board of Canada report.

‘Despite U.S. President Trump rolling back climate-friendly policies, the world is moving toward a cleaner, low-carbon economy and this represents a huge opportunity for Canadian companies,’ said Jacqueline Palladini, Senior Economist, The Conference Board of Canada. ‘Canadian innovators, investors, and producers can play a key role in helping the world’s businesses decrease their carbon footprint and lessen adverse environmental impacts by capitalizing on their global export strengths.’

Read more

Meet Alexia Hilbertidou, the 18-year-old founder of GirlBoss and the youngest person to be involved with Nasa’s Sofia missi

Alexia Hilbertidou may be the youngest person ever to go on a project mission with Nasa, but that’s not her only accolade.

The 18-year-old Aucklander is the founder of GirlBoss, a social enterprise which aims to empower women in science, technology, engineering and mathematics.

Hilbertidou started GirlBoss when she was a 16-year-old student at Albany Senior High, the result of being the only girl in her IT and physics classes.

Read more

CSL vows to fight rival’s patent claim

VACCINES and blood products developer CSL says it will vigorously fight a patent infringement claim launched by US-based biotech Bioverativ in relation to CSL’s haemophilia B drug, Idelvion.

Bioverativ, which develops treatments for haemophilia and other rare blood disorders, has filed complaints in the US District Court with the International Trade Commission. It claims that Idelvion infringes three Bioverativ patents.

Read more

Delaying action on car emissions will make Australia more vulnerable

France has set its car manufacturers the goal of halting sales of diesel and petrol cars by 2040. The announcement last week came a day after the Swedish manufacturer Volvo declared it will build only hybrid and electric cars from 2019.

Moving away from highly polluting cars is an urgent global priority. Worldwide, transport accounts for 26% of humanity’s carbon dioxide emissions and, of these emissions, 81% comes from road transport.

Read more

CSL in battle over Haemophilia drug

AUSTRALIAN vaccines and blood products developer CSL will vigorously fight a new patent infringement claim in relation to its haemophilia B drug, Idelvion.

US-based biotechnology group Bioverativ has filed complaints in the US District Court for the District of Delaware and with the International Trade Commission.

Read more

Premier encourages farmers to innovate

Premier Li Keqiang encouraged farmers to learn advanced agricultural technology and start their own business, while visiting an agricultural high-tech industrial zone in Northwest China’s Shaanxi province, on July 10.

There are now over 80 farmers being trained in the industrial park, so that they can be more knowledgeable about starting businesses back in their hometowns. On seeing the Premier, they were so excited and competed to introduce their business plan.

Premier Li urged local government to cultivate more talent and make institutional innovations, before popularizing their success to other places.

Read more

ProMIS Neurosciences Provides Second Quarter Update for 2017 and Outlook for Near-Term Value Creation

ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today provided a corporate update for the second quarter of 2017, including key accomplishments, a status update on ongoing programs, and the Company’s outlook for near-term value creation.

A narrated corporate overview of second quarter 2017 progress and outlook for the future is available on the ProMIS Neurosciences website at:  http://bit.ly/2tRLGAI .

Key accomplishments in the second quarter of 2017 and near-term value drivers include:

· Expansion of potential best in class amyloid-beta (AB) portfolio for Alzheimer’s disease
· Designated PMN350 as second validated product lead; in vivo data and biologic evidence of neuronal protection against toxic AB oligomers

Read more

Race Joint Venture With TargImmune

Race Oncology Limited (ASX: RAC) announced today that it has executed a Letter
of Intent with TargImmune Therapeutics AG (Basel, Switzerland) to enter into a
joint venture between the two companies. The joint venture, to be called Race
Immunotherapeutics, will focus on developing new and improved cancer therapies
based on combining Bisantrene with TargImmune’s targeted cancer therapy
technology.

The Race Immunotherapeutics (“RITX”) joint venture will be a 50:50 partnership
between Race and TargImmune, and all new intellectual property created by RITX
will be equally co-owned by the parties through their ownership of the joint
venture. RITX will be independently funded and operations of the joint venture
will commence once funding is in place and formal agreements executed. Final
terms of the joint venture agreement are subject to approval of both companies’
boards. All core development work will be conducted by TargImmune scientists
in Basel, under the guidance of a steering committee that includes Race
scientific staff. Race will provide scientific support and Bisantrene drug
product, but no direct funding to the Joint Venture.

Read more